SCHEMBL6413221

SCHEMBL6413221

CN1C(=O)c2ccccc2C(C(=O)Nc2ccccn2)C1c1cc(C(F)(F)F)cc(C(F)(F)F)c1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.55
CYP2C9 P11712 2/20 0.55
HSD17B10 Q99714 4/20 0.51
MAPT P10636 2/20 0.51
ALDH1A1 P00352 2/20 0.51
KDM4E B2RXH2 2/20 0.51
TSHR P16473 2/20 0.51
LMNA P02545 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
GAA P10253 2/20 0.47
NPC1 O15118 1/20 0.46
ALOX15 P16050 2/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C19 P33261 1/20 0.42
TRPM8 Q7Z2W7 1/20 0.41
FFAR1 O14842 1/20 0.41
HTT P42858 1/20 0.41
GLA P06280 1/20 0.41
CASP1 P29466 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6410777 0.90 GAA (0.48) CYP1A2CYP2C9HSD17B10MAPTALDH1A1
SCHEMBL6416746 0.90 TSHR (0.51) CYP1A2CYP2C9HSD17B10MAPTALDH1A1
SCHEMBL6411959 0.90 CYP2C9 (0.51) CYP1A2CYP2C9HSD17B10MAPTALDH1A1
SCHEMBL6414250 0.90 TSHR (0.49) CYP1A2CYP2C9HSD17B10MAPTALDH1A1
SCHEMBL6413379 0.89 TSHR (0.51) CYP1A2CYP2C9HSD17B10MAPTALDH1A1
SCHEMBL6417898 0.87 ALDH1A1 (0.69) CYP1A2CYP2C9HSD17B10MAPTALDH1A1
SCHEMBL6417623 0.87 MAPT (0.56) CYP1A2CYP2C9HSD17B10MAPTALDH1A1
SCHEMBL6410201 0.86 GAA (0.52) CYP1A2CYP2C9HSD17B10MAPTALDH1A1
SCHEMBL6413166 0.85 GAA (0.45) CYP1A2CYP2C9HSD17B10MAPTALDH1A1
SCHEMBL6410230 0.85 HSD17B10 (0.46) CYP1A2CYP2C9HSD17B10MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis AXYS PHARMACEUTICALS, INC. (US) 2005-06-09 US claimed
WO-2004004727-A1 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS AXYS PHARMACEUTICALS, INC. (US) 2004-01-15 WO claimed
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis AXYS PHARMACEUTICALS, INC. (US) 2005-06-09 US disclosed
WO-2004004727-A1 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS AXYS PHARMACEUTICALS, INC. (US) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis CASP3, BAX, BAD CYP1A2 1053/4885CYP2C9 2171/4885HSD17B10 1460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.